IMMUcan has completed patient enrolment

EORTC is very proud to inform you that as of October 30th, we have successfully completed patient enrolment in the IMMUcan project.

The IMMUcan project is an international public-private consortium of 30 partners running an integrated immuno-oncology profiling platform under the leadership of EORTC and Merck. The objective is to understand the interplay between cancer cells and the immune system and the impact of therapeutic interventions.

To that end, high-quality human biological material and clinical data are being collected from up to 3,000 patients with colorectal, lung, head & neck, breast and gastric cancers. The broad molecular and cellular profiling data generated from various immunoprofiling techniques are integrated with the longitudinal clinical data and used for the discovery of novel biomarkers to further document our understanding of resistance mechanisms to immunotherapy. More information about IMMUcan can be found here.

Today, we proudly celebrate reaching our goal of prospectively enrolling 1,472 patients via the EORTC SPECTA platformThanks to the collaboration with non-EORTC clinical groups providing access to their clinical studies, the total number of patients enrolled in IMMUcan has reached 2,650, all of whom will undergo comprehensive molecular and cellular profiling.

A heartfelt thank you to all the patients and investigators whose dedication and involvement made this remarkable achievement possible!

Analysis of the collected datasets will continue within IMMUcan in 2025.
Stay tuned for more updates to come!

IMMUcan receives funding from the European Union (grant 821558) within the Innovative Medicine Initiative 2 program and from the European Federation of Pharmaceutical Industries. IMMUcan is a #SPECTAplatform downstream project. The SPECTA Platform is supported by Alliance Healthcare. Alliance Healthcare will become Cencora.